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Abstract: Immune adjuvants are added to vaccines in order to enhance the immune response to an antigen. Muramyl dipeptide,  
N-acetylmuramyl-L-alanyl-D-isoglutamine, is the smallest structural unit of peptidoglycans showing the immunostimulating activity. Muramyl 
dipeptide analogues without the hydrophilic N-acetylmuramyl moiety are called desmuramyl peptides. Here, we provide review of desmuramyl 
peptides which were synthesized in order to improve the pharmacological properties of parent muramyl dipeptide, including our results 
regarding adamantane containing derivatives. Approach for future design of novel immunostimulators based on multiple pathogen recognition 
receptor activation was also considered. 
 





MMUNIZATION helps to inhibit the spread of infectious 
and cancer diseases. Vaccines can be used 
prophylactically in order to prevent the effect of infection, 
and therapeutically such as vaccines against cancer. 
Prophylactic vaccines stimulate immune systems to 
respond rapidly to pathogens and eliminate them.[1] 
Vaccines are manufactured on the basis of well charac-
terized antigens, but their immune response is often weak, 
largely because of the inability of the antigens to induce 
maturation of dendritic cells (DCs), the primary antigen-
presenting cells (APCs) that react to foreign pathogens and 
trigger the immune response.[1] Since the early 20th 
century, the concept of vaccine adjuvant was introduced. 
Immune adjuvant is a part of a vaccine that enhances the 
immune response to an antigen, either by the ability to 
form a depot which extends antigen exposure to APCs or by 
direct interaction with APCs.[1,2] Mineral compounds 
(aluminium based adjuvants), bacterial products, oil-based 
emulsions and liposomes have been evaluated as 
adjuvants. Adjuvants can be classified according to 
different criteria. Based on their mechanism of action they 
can be divided into two groups; delivery system (particulate 
adjuvants) and immune potentiators (immunostimulatory 
adjuvants). Delivery systems include mineral salts, lipid 
particles and microparticles.[3] 
 Aluminium based adjuvants are the most wide-
spread and the most preferred for human applications. 
Besides aluminium salts, FDA has licensed oil-in water 
emulsions (MF59 and AS03), AS04 (3-O-deacylated 
monophosphoryl lipid A (MPL) plus aluminum salts), CpG 
ODN and AS01 (MPL and saponin QS-21 formulated in 
liposomes) for human vaccines.[4] Freund’s adjuvants are 
one of the most powerful and widely used oil-water 
emulsion adjuvants in experimental immunology. Freund’s 
complete adjuvant (FCA) contains heat-killed mycobacteria 
(Mycobacterium tuberculosis) and Freund’s incomplete 
adjuvant is oil-water emulsion without mycobacteria 
added. They are extensively used in animal experimental 
models due to their high efficacy.[5] It was discovered that 
peptidoglycan, a bacterial cell wall polymeric component, 
is active part of the FCA. 
 In 1974 it was shown that muramyl dipeptide (MDP, 
N-acetylmuramyl-L-alanyl-D-isoglutamine) is the smallest 
peptidoglycan fragment (Figure 1) capable of replacing 
whole mycobacterium in FCA.[6] MDP acts as an immune 
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Immune potentiators in general activate immune res-
ponses through pattern-recognition receptors (PRRs) or 
directly, for example by cytokines. PRRs are classified into: 
Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), NOD-
like receptors (NLRs) and C-type lectin receptors (CLRs).[7] 
Muropeptides, breakdown products of polymeric peptido-
glycan, act as agonists of PRRs and therefore exhibit 
immunostimulatory properties.[8–10] They activate innate 
immune responses and contribute to the development of 
adaptive immunity. 
 Numerous MDP analogues and derivatives were 
synthesized, in order to improve the pharmacological 
properties of MDP, such as pyrogenicity, poor cellular 
penetration, rapid elimination, the toxicological profile, for 
possible clinical application.[11–13] Mifamurtide (liposomal 
muramyl tripeptide phosphatidyl ethanolamine, L-MTP-PE, 
Figure 2) is used in clinics for treatment of osteocarcinoma. 
L-MTP-PE activates the immune response and in addition 
to standard chemotherapy it enables the statistically 
significant reduction in the risk of death from osteo-
sarcoma.[14] Another example of safe MDP derivative is 
murabutide (Figure 2). Murabutide interacts with cells of 
innate and adaptive immune system and enhance the 
resistance against microbial infections.[15] 
 MDP analogues without the N-acetylmuramyl 
moiety are called desmuramyl peptides (DMP). Structure-
activity studies of the MDP derivatives and analogues 
suggest that L-Ala-D-isoGln pharmacophore is essential for 
the immunostimulatory properties and that the intro-
duction of lipophilic substituent into MDP analogues can 
increase its adjuvant activity.[11] The desmuramyl dipep-
tides were shown to enter the cell by passive absorption, 
which is directly dependent on their lipophilicity.[16] The 
absence of structural data for the binding site of MDP  
untill 2016 has made the design of novel DMP 
immunostimulators difficult.[17] Till then the structure-
activity relationship studies of known compounds with 
immunostimulation properties were the only route for 
rational drug design of novel adjuvants. In this article is 
given an overview of the most important DMP structural 
scaffolds.  
 
MECHANISM OF ACTION  
MDP triggers an immune response by activating the 
mammalian NOD-like receptor, nucleotide binding oligo-
merization domain-containing protein 2 (NOD2). NOD2, 
also known as NLRC2 or CARD15, is an intracellular protein 
(1040 residues, 110 kD) involved in signalling response to 
peptidoglycan fragment which is recognized as a pathogen-
associated molecular pattern (PAMP). NOD2 belongs to 
signal transduction ATPases associated with numerous 
domains (STAND) and is composed of two N-terminal 
caspase recruitment domains (CARDs), a central nucleotide 
oligomerization domain (NOD) and leucine-rich repeat 
domain (LRR) which is believed to act as MDP sensor.[18] 
Maekawa et al have determined crystal structure of ADP-
bound NOD2. They confirmed that LRR domain of NOD2 
consists of ten LRR and that previously proposed MDP-
binding site is on the concave surface of the LRR domain.[17] 
The NOD domain contains several subdomains; a 
nucleotide-binding domain (NBD), a winged-helix domain 
(WHD) and two helix domains (HD1 and HD2). Closed and 
inactive form of NOD2 is characterized by ADP-mediated 
packed conformation which is stabilized by interaction 
between WHD, and NBD and HD1. Hydrophobic pocket 
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suitable for accommodating glycan or peptide part of MDP, 
formed by amino acid residues highly conserved among 
different species of NOD2, was also determined.[19] 
 Lauro with coworkers[19] have defined, using surface 
plasmon resonance methodology, the critical residues 
responsible for NOD2-MDP interaction, namely, Arg857, 
Trp911 and Ser913. They concluded that the sugar and 
peptide portions of MDP contribute to the binding and that 
aromatic Trp911 residue is involved in carbohydrate-
binding site.[19] 
 Upon MDP binding, HD2 mediates conformational 
changes of the NBD, WH, and HD1 to allow ADP-ATP 
exchange, oligomerization which induces a signalling 
complex named nodosome and downstream signalling. 
After interaction between the LRR domain and MDP  
(Figure 3), a complex conformational changes appear that 
result in protein oligomerization and then further the 
effector CARDs mediation of intracellular signalling via the 
nuclear factor-kappa B (NF-κB) pathway to activate innate 
immunity through macrophage response as well as adap-
tive immunity through the production of antigen-specific  
T-cells.[20] 
 MDP binding to NOD2 was also proven by 
biophysical and biochemical assays.[18,21] Grimes and 
coworkers have shown that the binding between MDP and 
NOD2 is pH dependent and that it occurs in acidic pH 
(optimal pH range is from 5.0 to 6.5).[18] To support this, 
Lauro and others demonstrated in lysis experiment that 
NOD2 forms insoluble pellets between pH 5 to 6 because of 
binding to peptidoglycan fragments and by pH increasing 
over pH 8.5 it became soluble, suggesting that NOD2 is no 
longer bound to peptidoglycan fragments.[19] 
 Upon MDP recognition, NOD2 undergoes self-
oligomerization and activates the serine-threonine kinase 
receptor-interacting protein 2 (RIP2). Active RIP2 leads to 
ubiquitination of NF-κB. Subsequently, the NF-κB and 
mitogen-activated protein kinase (MAPK) signaling path-
ways are initiated, resulting in the production of cytokines 
and certain antimicrobial peptides and the induction of 





DMP derivatives described in the literature mostly 
comprise a lipophilic moiety linked to the dipeptide core 
structure in order to improve pharmacological properties. 
In general, the most active ones have cyclic substituents.[23] 
First desmuramyl peptides showing common activities like 
MDP were carbocyclic MDP analogs I and II (Figure 4) which 
also exhibited antitumor activity.[24,25] A carbocyclic MDP 
analogue II with trans-2-[[2′-(acetylamino)cyclohexyl]oxy]-
acetyl group and D-isoglutamine instead of D-glutamic acid, 
in contrast to MDP, was apyrogenic and nontoxic.[25] 
 N-Acetylmuramic acid (MurNAc) was in the 
continuation of DMP research replaced by phthalimido, 
LK423, and adamantyl substituents, LEK415 and LEK517 
derivatives, shown in Figure 5. LK423 upregulated inter-
leukin-10 (IL-10) gene expression in the spleen of cyclo-
phosphamide treated mice.[26] Additionally, phtalimido 
desmuramyl dipeptide LK423 showed potential as 
therapeutic agent for inflammatory bowel disease. Treat-
ment of mice with dextran sulfate sodium-induced colitis 
by subcutaneous low dose LK423 injections resulted in 
delaying the progression of inflammation in the colon.[27] It 
was also demonstrated that colon-specific delivery of LK-
423 by microcapsules composed of pectin cores enhances 
the therapeutic effect of the drug in treating ulcerative 
colitis in rats.[28] Furthermore, LK423 stimulated the 
production of tumor necrosis factor (TNF) in vitro at 
phorbol 12-myristate 13-acetate (PMA) and ionomycin-
stimulated cultures of human peripheral blood 
mononuclear cells (PBMCs).[29]  
 Phthalimido-desmuramyl dipeptide LK423 was ad-
ditionally modified giving the phosphono analogues.[30,31] 
Derivative LK415[32] is adamantane analogue of LK423, 
while LK517 is phosphonate analogue of LK415, as shown 
at Figure 5. LK423, LK415 and LK517 are strong regulators 
of IL-12 and interferon IFN-γ synthesis. Furthermore, 
introduction of the phosphonate moiety in LK415 showed 
to be important for the increase of T-cell cytokine 
production.[23,31] 
 
Figure 3. NOD2 changes upon MDP binding. 
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 Mašek with coworkers[33] have synthesized another 
adamantane substituted desmuramyldipeptide, adamantyl-
amide dipeptide (AdDP) which contains 1-adamantamine, 
known antiviral agent, linked to carboxylic group of  
D-isoglutamine. AdDP was shown to be an effective and  
non-toxic immunoadjuvant.[33,34] In BALB/c mice using 
ovalbumin (OVA) as an antigen, dose–response relation-
ship was observed on the anti-OVA antibody production, 
when AdDP was used by the intraperitoneal or oral 
administration route. The IgG isotype analysis points out 
that AdDP stimulates enhancement of IgG1 antibodies 
which is associated with a dominant Th2 response.[34]  
 Furthermore, attachment of adamantyl group to 
DMP core structures was also used for the preparation of 
immunostimulating adamantyl tripeptides in which the  
N-acetylmuramic portion of MDP was replaced with 
adamantyl glycine. Diastereoisomers of adamant-1-yl 
tripeptides IIIa and IIIb[35] and adamant-2-yl tripeptides  
IVa and IVb[36] (Figure 6) were synthesized and shown  
to exhibit adjuvant (immunostimulating) activities in vivo, 
in the mouse model. All tested adamantyl tripeptides  
did not show a tendency to modulate the OVA-specific 
response towards more pronounced Th1 or Th2 type of 
immune response, even though pronounced difference  
in IgG1 response was observed, similarly as with AdDP 
derivative. 
 Researchers from Faculty of Pharmacy, University of 
Ljubljana have investigated DMPs with saccharine, indole 
and pyrrolo/pyrido-fused[1,2]benzisothiazol moieties.[37–39] 
Different heteroaromatic ring systems were considerd as  
π-electronic substititutes for the glucosamine residue of 
MDP. Initial screening of their immunomodulatory 
properties were performed in vitro, evaluating their effect 
on lipopolysaccharide (LPS)-induced cytokine release in 
human monocytic cell line THP-1. Selected compounds and 
murabutide as reference compound were further inves-
tigated using LPS and PMA/ionomycin-stimulated human 
PBMCs. Indole scaffold-based compounds V and VI 
(Figure 7) proved to be effective down-modulators of 
proinflammatory cytokine synthesis and desmuramyl-
dipeptide VII with a pyrido-fused [1,2]-benzisothiazole 
moiety and ethyl ester functionality, significantly enhanced 
the production of multiple proinflammatory cytokines 
(TNF-α, IL-6, IL-1b and IL-8).[37] Based on these results 
second generation of lipophilic DMPs with heteroaromatic 
scaffolds were synthesized and biologically evaluated.[38] In 
order to increase lipophilicity furthermore, carboxylic 
groups of dipeptide were replaced by ethyl ester. Their 
Nod2-agonistic activity were screened using Nod2-
transfected HEK-Blue Nod2 cells, and subsequently their 
effect on the proinflammatory cytokine production of 
PMA/ionomycin-stimulated human PBMCs was evaluated 
relative to that of murabutide.[38] The most active were 
DMPs VIII and IX so they were candidates for further 
studies (Figure 7). 
 Indol moiety proved to be an appropriate surrogate 
for the MurNAc of MDP and introduction of ester 
functionality has allowed better internalization of 
compounds into cell. Therefore, minor modifications of hit 
compound acyl Gly-L-Ala-D-Glu derivative VII was 
performed and compound X (Figure 8) with a  
6-phenylindole moiety, was identified as the strongest 
NOD2 agonist in this class of indole-scaffold based 
compounds, enabling a deeper understanding of the 
structural requirements of DMPs for NOD2 activation.[39] 
 
Figure 6. Adamantyl tripeptides. 
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 Further improvement of aromatic DMPs based on 
cinnamoylglycine as an MurNAc surrogate, lead to the next 
generation of acyl tripeptides which NOD2-dependet NF-κB 
activation capacity was determined on human embryonic 
kidney 293 cells (HEK293) overexpressing the NOD2 
gene.[40] Compound XI was identified as the most potent 
NOD2 agonist of the DMP class, so far. Results indicate that 
cinnamoylglycine is an efficient surrogate of MurNAc and 
that increase of lipophilicity, by introduced ethyl ester 
functionality and addition of lipophilic L-Ala substituent, 
stimulate the immune responce. It also augmented LPS 
induced pro-inflammatory cytokine release from PBMCs as 
well as the increase of OVA-specific IgG titers in a mouse 
model. These findings indicate that XI can induce both 
innate and adaptive immune responses.[40]  
 Liu and coworkers[41] have also prepared aromatic 
DMP, twenty DMP derivatives in which benzoic acid with 
different substituents in the positions 2, 4 and 5 of the 
phenyl ring was attached to the L-Ala-D-isoGln core peptide 
structure. They exhibited strong adjuvant activity and have 
enhanced the antigenicity of hepatitis B surface antigen 
(IPQSLDSWWTSL).[41] Beside described lipophilic DMP 
derivatives several amphiphilic derivatives were described 
in the literature (Figure 9). Our group has prepared 
mannosylated adamantyl tripeptides with immuno-
stimulating activity.[42] Mannose was attached to the 
desmuramyl dipeptide because it may contribute to the 
recognition of the adjuvant compound by specific mannose 
receptors expressed at immune cells. It is known that 
mannosylated drug delivery systems enhance uptake and 
activation of dendritic cells and increase T cell prolife-
ration.[43–46] Mannosylation of the adamantylated des-
muramyl peptides amplified the adjuvant activity in 
experiments in vivo.[42,46] Different isomers of mannosyl-
ated adamantyl tripeptides, regarding the chiral centers 
introduced at adamantyl glycine and spacer connecting the 
sugar part to the adamantyl tripeptide were synthesized 
and biologically evaluated.[42,46] Introduction of mannose 
has significantly stimulated the immune response. We 
assume that mannose effects the immune response by 
mannose receptors family, group I CLRs, present on 
immunocompetent cells (such as macrophages and 
dendritic cells).[47,48] The most active ManAdTP derivative 
(Figure 9) which have a D-configuration at the (adamant-1-
yl)glycine moiety and (R)-configuration on hydroxy-
isobutyryl linker was used as a hit compound for the design 
of new ones. Two series of compounds were prepared: (i) 
derivatives containing glycolyl linker between mannose 
and dipeptide, and (ii) derivatives containing (R)-hydroxy-
isobutyryl linker. In both series, positions of adamantane 
 
Figure 7. Indole scaffold and pyrido-fused [1,2]-benziso-
thiazole based desmuramyl peptides. 
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binding (to N- or C-terminus) were altered in comparison 
with derivatives lacking adamantane moiety.[49] Glycolic 
linker was introduced because it was demonstrated that  
N-glycolyl muramyl peptides induce significantly higher 
activation of NOD2 than MDP.[50,51] Immunostimulating 
properties of synthesized derivatives were assessed in vivo 
using ovalbumin as an antigen. All mannosylated peptides 
with glycolyl linker exhibited higher adjuvant activity than 
analogues with hydroxyisobutyryl linker. It was observed 
that the most suitable position of adamantane in this class 
of compounds is at peptide N-terminus. Compound XII was 
identified as the most potent adjuvant in this class of 
mannosylated desmuramyl peptides, so far.[49] 
 Jiang with coworkers[52] have prepared amphiphilic 
DMP derivatives in which muramic acid was replaced with 
a hydrophilic arene and lipophilic chain was introduced to 
the peptide. The hydrophilic aromatic amines were 
connected by glycolic acid linker to the N-terminus of  
L-alanine-D-isoglutamine dipeptide. The glycolic acid linker 
was added at the peptide end in order to facilitate their 
penetration through cell membrane. The XIII and XIV DMPs  
(Figure 9) were found to modulate the immune response 
by amplifying the LPS-induced surface glycoprotein (ICAM-1) 
expression in THP-1 cells without showing significant 
toxicity. Furthermore, these compounds were able to 
trigger the secretion of higher levels of pro-inflammatory 
cytokine (TNF-α) than the murabutide.[52] It can be 
concluded that balanced lipophilicity and hydrophilicity is 
important for the exhibition of biological activity of DMP.  
 
FUTURE PERSPECTIVE 
Development of new adjuvants in future will be focused on 
safe adjuvants which will generate multifaceted immune 
responses and consequently enable tuning of disease-
specific immune responses. Therefore, the PRR pathways 
represents an attractive source of novel adjuvants for 
vaccines. Triggering of certain PRR can induce diverse 
immune responses through complex signaling processes 
which depend on crosstalk with other PRRs. Application of 
multi-PRR activation approaches can increase immunity 
significantly.[53] For example, NOD2 agonists act synergistic-
ally and enhance the adjuvant activity of TLR ligands.[54–56] 
Furthermore, a combination of NLR/TLR ligands induce 
Th1-polarized response. Another example of dual adjuvant 
system represents CLR/TLR ligands.[57] Glycan structures 
build up tumor antigens and regulate immune reaction by 
specific binding to CLRs. Therefore, compounds with 
expressed CLR agonist or antagonist properties could also 
be considered as potential agents for cancer immuno-
therapy.[58,59] Desmuramyl peptide-based agents can be 
used for immunotherapy in the treatment of cancer, for 
example DMP paclitaxel conjugates.[60,61] 
 Preparation of appropriate formulations acting as 
delivery systems represents another approach for the 
design of efficient adjuvants. Strength and mechanisms of 
immunostimulation induced by nanocarrier vaccines 
depend on chemical composition, particle size and 
homogeneity, charge, nature and location of antigens 
and/or adjuvants within the delivery systems. Liposomes 
are often used carrier systems. Liposome characteristics 
can be adjusted in order to achieve desired properties. 
Water-soluble compounds can be entrapped within the 
aqueous inner space, whereas lipophilic ones can 
intercalate into the lipid bilayer. Modifications of liposomes 
can additionally broaden their application. Modifications 
can be performed by attachment of antigens and/or 
adjuvants on liposome surface either by adsorption or 
stable chemical linking.[62] In several studies reported 
earlier, adamantane-based DMP derivatives were incor-
porated into liposomes.[63–65] Studies have confirmed that 
liposomal formulations can improve biological activity and 
that adamantyl moiety incorporates into the lipid core of 
the bilayer due to its lipophilic properties.[66] 
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Design of novel efficient adjuvants is based on knowledge 
of their mechanisms of action and previously performed 
structure-activity relationship studies. Muramyl dipeptide-
based immunostimulators are important class of com-
pounds for the development of novel adjuvants. 
Modification of desmuramyl dipeptide core with lipophilic 
substituents based on aromatic and adamantane struc-
tures, and preparation of amphiphilic desmuramyl peptide 
derivatives represents a perspective approach for the 
development of novel adjuvants.  
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